543 related articles for article (PubMed ID: 31286471)
1. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
[TBL] [Abstract][Full Text] [Related]
4. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
[TBL] [Abstract][Full Text] [Related]
5. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
[TBL] [Abstract][Full Text] [Related]
6. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
Robinson A; Kardos M; Kimball AB
J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
8. Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician's Global Assessment (PGA) in Psoriasis Clearance.
Wu AG; Conway J; Barazani L; Roy B; Cline A; Pereira F
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1155-1163. PubMed ID: 32804321
[TBL] [Abstract][Full Text] [Related]
9. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Bożek A; Reich A
Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
[TBL] [Abstract][Full Text] [Related]
10. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
11. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
12. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
[TBL] [Abstract][Full Text] [Related]
13. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
Mrowietz U; Warren RB; Leonardi CL; Saure D; Petto H; Hartz S; Dossenbach M; Reich K
J Eur Acad Dermatol Venereol; 2021 May; 35(5):1161-1175. PubMed ID: 33480102
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
Feldman SR; Regnier SA; Chirilov A; Hey F; Gilloteau I; Cella D
J Am Acad Dermatol; 2019 Jun; 80(6):1650-1657. PubMed ID: 30703461
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
[TBL] [Abstract][Full Text] [Related]
16. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
17. Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Navarro Ruiz A; Toledo Alberola F; Aceituno S;
Farm Hosp; 2024; 48(2):51-56. PubMed ID: 37739901
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
19. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Ruiz AN; Alberola FT; Aceituno S;
Farm Hosp; 2024; 48(2):T51-T56. PubMed ID: 38148255
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).
Orsini D; Caldarola G; Dattola A; Campione E; Bernardini N; Frascione P; De Simone C; Richetta AG; Galluzzo M; Skroza N; Assorgi C; Amore E; Falco GM; Gaeta Shumak R; Artosi F; Maretti G; Potenza C; Bianchi L; Pellacani G; Peris K; Bonifati C; Graceffa D
J Dermatolog Treat; 2024 Dec; 35(1):2319304. PubMed ID: 38413097
[No Abstract] [Full Text] [Related]
[Next] [New Search]
